Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 15
- Registration Number
- NCT06409390
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 200
- Registration Number
- NCT06341283
- Locations
- 🇨🇳
Clinical Research Center, Qingdao, Shandong, China
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 138
- Registration Number
- NCT06257264
- Locations
- 🇺🇸
Hoag Memorial Presbyterian, Newport, California, United States
🇦🇺Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇨🇳Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 78
- Registration Number
- NCT06253195
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06239467
- Locations
- 🇺🇸
SCRI Oncology Partners - Nashville, Nashville, Tennessee, United States
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
🇫🇷Centre Antoine Lacassagne, Nice, France
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Conditions
- Locally Advanced Unresectable HER2-Negative Breast CarcinomaMetastatic HER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Locally Advanced Unresectable Hormone Receptor-Positive Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AnastrozoleProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Diagnostic ImagingDrug: ExemestaneOther: Fludeoxyglucose F-18Drug: Fluorine F 18 Fluoro Furanyl NorprogesteroneDrug: FulvestrantBiological: Gonadotropin-releasing Hormone AnalogDrug: LetrozoleProcedure: Positron Emission TomographyDrug: TamoxifenDrug: Therapeutic Estradiol
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT06179303
- Locations
- 🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorAdvanced Breast CancerMetastatic Breast CancerHormone-receptor-positive Breast CancerHormone Receptor Positive Breast CarcinomaHormone Receptor Positive Malignant Neoplasm of BreastHER2-negative Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 79
- Registration Number
- NCT06120283
- Locations
- 🇺🇸
Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT06110793
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT06105632
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇨🇦CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, Quebec City, Quebec, Canada
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.